Edlund C, Sabouri S, Nord C E
Department of Immunology, Microbiology, Pathology and Infectious Diseases, Huddinge University Hospital, Karolinska Institute, Sweden.
Eur J Clin Microbiol Infect Dis. 1998 Mar;17(3):193-5. doi: 10.1007/BF01691117.
The in vitro activity of BAY 12-8039 against 360 anaerobic clinical isolates was determined by the agar dilution method and compared to that of five other antimicrobial agents. BAY 12-8039 and imipenem were the most active agents tested. The following MIC90 values were determined for BAY 12-8039: Peptostreptococcus spp. (50 isolates), 1 mg/l; Propionibacterium acnes (30 isolates). 0.25 mg/l; Clostridium perfringens (30 isolates), 0.5 mg/l; Clostridium difficile (50 isolates), 2 mg/l; Bacteroides fragilis (50 isolates), 1 mg/l; non-fragilis Bacteroides, Porphyromonas, and Prevotella spp. (100 isolates), 2 mg/l; and Fusobacterium spp. (50 isolates), 0.25 mg/l. The results of the present study show that BAY 12-8039 may be useful in the treatment and prophylaxis of anaerobic infections.
采用琼脂稀释法测定了BAY 12 - 8039对360株临床厌氧菌分离株的体外活性，并与其他五种抗菌药物进行了比较。BAY 12 - 8039和亚胺培南是测试的活性最强的药物。测定了BAY 12 - 8039的以下MIC90值：消化链球菌属（50株分离株），1mg/L；痤疮丙酸杆菌（30株分离株），0.25mg/L；产气荚膜梭菌（30株分离株），0.5mg/L；艰难梭菌（50株分离株），2mg/L；脆弱拟杆菌（50株分离株），1mg/L；非脆弱拟杆菌、卟啉单胞菌和普雷沃菌属（100株分离株），2mg/L；梭杆菌属（50株分离株），0.25mg/L。本研究结果表明，BAY 12 - 8039可能对厌氧菌感染的治疗和预防有用。
